News

Xadago Shows Potential in Small Study to Ease Urinary Problems

Xadago (safinamide) — approved as an add-on therapy to ease “off periods” that can accompany levodopa — may also help with urinary symptoms in people with Parkinson’s disease, a small study reports. These early findings support previous studies showing that Xadago may be addressing Parkinson’s non-motor symptoms. Larger studies are needed…

Adamas Aquires Global Rights to Osmolex ER for Motor Symptoms

Adamas Pharmaceuticals has acquired global rights to the Parkinson’s disease medication Osmolex ER (amantadine hydrochloride), used to treat motor symptoms, including those caused by other therapies. The purchase, worth $7.5 million, was part of a settlement agreement with the medicine’s developer, Osmotica Pharmaceutical US, according to a…

More Reliable Alpha-synuclein Test Speeds Diagnosis

Researchers have developed a faster method of measuring the rate at which alpha-synuclein protein forms toxic clumps that reliably distinguishes people with Parkinson’s disease from those without the condition. The findings support the use of this test — which cuts by more than half the time required to obtain…

Sex, Age and Family History Seen to Raise Parkinson’s Risk

Older age, male sex, and a family history of Parkinson’s disease appear to associate with a higher risk of developing Parkinson’s later in life, according to an Italian study. The research also suggested that dietary choices and work history influenced the disease’s development, with those who consumed meat on…